Bionor Immuno Release: Researchers Find That Vacc-4x Therapeutic ...
21 Oct 2009 ... Bionor Immuno Release: Researchers Find That Vacc-4x Therapeutic Peptide-Based HIV Vaccine Increases CD4 T-Cells in Chronically Infected ...
http://www.biospace.com/news_story.aspx?NewsEntityId=159998...
|
Bionor Immuno / research
Multiple antigen concentrations in delayed-type hyper- sensitivity (DTH) and ... HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or ...
http://www.bionorimmuno.com/publications.html...
|
Bionor Immuno Welcomes Renowned Virologist Robert Redfield, MD...
The vaccine conference is sponsored by the Global HIV Vaccine Enterprise and ... as well as the intradermal skin test delayed type hypersensitivity (DTH). ...
http://www.biospace.com/news_story.aspx?NewsEntityId=159592...
|
Multiple antigen concentrations in delayed-type hypersensitivity ...
1: Vaccine. 2006 Mar 6;24(10):1543-50. Epub 2005 Nov 2. ... Bionor Immuno AS, P.O. Box. 1823, NO-3703 Skien, Norway. jorgen.nyhus@bionorimmuno.com. Delayed-
type hypersensitivity (DTH) testing represents a simple in vivo method for ...
peptide-based HIV-1 immunotherapy candidate Vacc-4x, we monitored DTH responses
...
http://www.ncbi.nlm.nih.gov/pubmed/16289707...
|
Therapeutic vaccines against HIV and AIDS
Therapeutic HIV vaccine trials at. Ullevål University hospital. • Vacc-4x (Phase II) (n=40) ... Differences in HIV-RNA. HIV RNA w52. DTH lo. DTH med. DTH hi ...
Bionor Immuno: Birger Sørensen. Maja A. Sommerfelt. Jørgen Nyhus ...
http://www.fhi.no/dav/4D6C78966B.pdf...
|
Comparable Immunogenicity Between Patients on or off Combination ...
1 Ullevål University Hospital, Oslo, Norway; 2 Bionor Immuno, Skien, Norway; and 3 Mericon, Skien,. Norway. Background: Optimal induction of HIV-specific
responses after ... peptide-based pentavalent therapeutic vaccine (Vacc-5q)
consisting of ... to DTH in vivo (Kvale, AIDS 2005). A comparison between C+ and
C- ...
http://www.bionorimmuno.com/Kvale_AIDSVacc06Abstract.pdf...
|
Slide 1
evolution of HIV variants over time within an HIV-infected patient. ... both in vitro and in vivo (DTH skin test) before ART was stopped according to protocol
.... the genomic region corresponding to the peptides included in the vaccine
...
http://www.bionorimmuno.com/Kran_et_al_KeystonePoster_A4.pdf...
|
